GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: PF-06939999 is an orally bioavailable, SAM-competitive PRMT5 inhibitor that was developed for ant-tumour potential [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| PF-06939999 has been advanced to clinical evaluation in splicing dysregulated non-small cell lung cancers. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03854227 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | Phase 1 Interventional | Pfizer | ||